Vunakizumab (Anti-CTLA-8 / IL-17a) | Interleukins antibody | Read Reviews & Product Use Citations

Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.

Purity & Quality Control

≥99

Choose Selective Interleukins Inhibitors

Biological Activity

Description	Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.

References
[1] Zhang C, et al. J Am Acad Dermatol. 2022;87(1):95-102.

References

[1] Zhang C, et al. J Am Acad Dermatol. 2022;87(1):95-102.

Product Details

CAS No.	1792181-33-9
Molecular Weight	146.28
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field